Low Dose Naltrexone (LDN) is taken at bedtime and prescribed doses range typically between 3mg and 4.5mg, but we can compound any dose desired.  Belmar Pharmacy’s LDN Tablets are immediate release and are scored in half for easy dose titration.  LDN is only available through compounding pharmacies and LDN Tablets are available only at Belmar Pharmacy.  
Belmar Pharmacy is a preferred pharmacy on the website: www.lowdosenaltrexone.org.


 Multiple Sclerosis
Frech, T., Novak, K., Revelo, M., Murtaugh, M., Markewitz, B., Hatton, N., Scholand, M., Frech, E.,    Markewitz, D. and Sawitzke, A. (2011). Low-Dose Naltrexone for Pruritus in Systemic               Sclerosis. International Journal of Rheumatology, 2011, pp.1-5.
Gironi, M., Martinelli-Boneschi, F., Sacerdote, P., Solaro, C., Zaffaroni, M., Cavarretta, R., Moiola, L.,     Bucello, S., Radaelli, M., Pilato, V., Rodegher, M., Cursi, M., Franchi, S., Martinelli, V., Nemni, R., Comi, G. and Martino, G. (2008). A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Multiple Sclerosis, 14(8), pp.1076-1083.
  Crohn's Disease 
Ccfa.org, (2016). CCFA: What is Crohn's Disease | Causes of Crohn's. [online] Available at:            http://www.ccfa.org/what-are-crohns-and-colitis/what-is-crohns-disease/ [Accessed 6 Jan. 2016].
Segal, Dan, John K Macdonald, and Nilesh Chande. "Low Dose Naltrexone for Induction of Remission in   Crohn's Disease." Cochrane Database of Systematic Reviews(2014). Print. 
Smith, J., Field, D., Bingaman, S., Evans, R. and Mauger, D. (2013). Safety and Tolerability of Low-dose Naltrexone Therapy in Children With Moderate to Severe Crohn’s Disease. Journal of Clinical Gastroenterology, 47(4), pp.339-345.
Smith, J., Bingaman, S., Ruggiero, F., Mauger, D., Mukherjee, A., McGovern, C. and Zagon, I. (2011). Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled Trial. Dig Dis Sci, 56(7), pp.2088-2097.
Lichtenstein, G., Hanauer, S. and Sandborn, W. (2009). Management of Crohn's Disease in Adults. Am J Gastroenterol, 104(2), pp.465-483.
Smith, J., Stock, H., Bingaman, S., Mauger, D., Rogosnitzky, M. and Zagon, I. (2007). Low-Dose Naltrexone Therapy Improves Active Crohn's Disease. The American Journal of Gastroenterology, 102(4), pp.820-828.
Woeller, K. (2009). Autism - The Benefits of Low Dose Naltrexone. [Blog] DR. KURT WOELLER -   BIOMEDICAL AUTISM INTERVENTION. Available at: http://drkurtwoeller.blogspot.com/2009/01/autism-benefits-of-low-dose-naltrexone.html [Accessed 4 Jan. 2016].
Bouvard, M., Leboyer, M., Launay, J., Recasens, C., Plumet, M., Waller-Perotte, D., Tabuteau, F., Bondoux, D., Dugas, M., Lensing, P. and Panksepp, J. (1995). Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Research, 58(3), pp.191-201. 
Ing, B., Au, D. and Poland, R. (1993). Low-Dose Naltrexone Inhibits Pemoline-Induced Self-Biting Behavior in Prepubertal Rats. Journal of Child and Adolescent Psychopharmacology, 3(2), pp.71-79.
Campbell, M., Anderson, L., Small, A., Adams, P., Gonzalez, N. and Ernst, M. (1993). Naltrexone in Autistic Children: Behavioral Symptoms and Attentional Learning. Journal of the American Academy of Child & Adolescent Psychiatry, 32(6), pp.1283-1291.
Sandman, C. (1990). The Opiate Hypothesis in Autism and Self-Injury. Journal of Child and Adolescent Psychopharmacology, 1(3), pp.237-248.
Campbell, M., Overall, J., Small, A., Sokol, M., Spencer, E., Adams, P., Foltz, R., Monti, K., Perry, R., Nobler, M. and Roberts, E. (1989).  Journal of the American Academy of Child & Adolescent Psychiatry, 28(2), pp.200-Naltrexone in Autistic Children: An Acute Open Dose Range Tolerance Trial.206.
Lowdosenaltrexone.org, (2016). The Low Dose Naltrexone Homepage. [online] Available at:                 http://www.lowdosenaltrexone.org/ [Accessed 4 Jan. 2016].
Ldninfo.org, (2016). The Low Dose Naltrexone Homepage. [online] Available at:           http://www.ldninfo.org [Accessed 4 Jan. 2016].
Donahue, R., McLaughlin, P. and Zagon, I. (2011). Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatinExperimental Biology and Medicine, 236(7), pp.883-895.
Younger, J. and Mackey, S. (2009). Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study. Pain Med, 10(4), pp.663-672.
Younger, J., Parkitny, L. and McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti- inflammatory treatment for chronic pain. Clin Rheumatol, 33(4), pp.451-459.
Chopra, P. and Cooper, M. (2013). Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN). Journal of Neuroimmune Pharmacology, 8(3), pp.470-476.
Pape, W. and Wöller, W. (2015). Low dose naltrexone in the treatment of dissociative symptoms. Nervenarzt, 86(3), pp.346-351.

Postural Orthostatic Tachycardia Syndrome (POTS)
and Mast Cell Activation Syndrome (MCAS)
Brook, J., Goodman, B., Myers, T., and Weinstock, L. (2017).  Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. British Medical Journal Case Reports, pp. 1-6.
Mischoulon, D., Hylek, L., Yeung, A., Clain, A., Baer, L., Cusin, C., Ionescu, D., Alpert, J., Soskin, D. and Fava, M. (2017). Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. Journal of Affective Disorders, 208, pp.6-14.

Clinical Practice
Schwaiger, Timothy, Md. (2018). The Uses of Low-Dose Naltrexone in Clinical Practice; Potential benefits for a wide range of conditions. Natural Medicine Journal, April 2018. 10 Issue 4. 

Belmar Pharmacy  800.525.9473  I  303.763.5533  I  231 Violet Street, Suite 140  I  Golden, CO 80401